Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Russell

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
The Lancet. Respiratory Medicine|May 26, 2018
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trialRichard J Russell, Latifa Chachi, J Mark FitzGerald, et al.
The European Respiratory Journal|August 31, 2019
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questionsArnaud Bourdin, Leif Bjermer, Christopher Brightling, et al.
The Lancet. Respiratory Medicine|March 27, 2022
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trialAhmed J Yousuf, Seid Mohammed, Liesl Carr, et al.
ERJ Open Research|October 1, 2024
1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort studyOlivia C Leavy, Richard J Russell, Ewen M Harrison, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
The Lancet. Respiratory Medicine|May 26, 2018
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trialRichard J Russell, Latifa Chachi, J Mark FitzGerald, et al.
The European Respiratory Journal|August 31, 2019
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questionsArnaud Bourdin, Leif Bjermer, Christopher Brightling, et al.
The Lancet. Respiratory Medicine|March 27, 2022
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trialAhmed J Yousuf, Seid Mohammed, Liesl Carr, et al.
ERJ Open Research|October 1, 2024
1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort studyOlivia C Leavy, Richard J Russell, Ewen M Harrison, et al.
Pageof 2